A number of promising drugs in the pipeline can lower hepatitis B virus (HBV) DNA and antigen levels. Some may offer a functional cure for selected individuals, but agents that offer a reliable cure for most patients are not yet on the horizon. This would be expected to substantially reduce the likelihood of liver disease progression
